- Trading session: 26 November 2026, 24‑hour period ending at 11:46 AM Central Europe
- Price change: Down 1.94 %
- Current price: USD 4.05
- Shares outstanding: 19.3 million
- Market capitalization: USD 78.3 million
- Volume traded in last 24 hours: USD 1.5 million
- Performance since last month‑end: Down 45.64 %
Technical Indicators
| Indicator | Value |
|---|
| 200‑day simple moving average | USD 8.72 |
| 52‑week high | USD 18.11 (28 Oct 2025) |
| 52‑week low | USD 3.93 (23 Oct 2026) |
| Ticker | Price Change | Current Price (USD) | Market Capitalization (USD mn) | P/E Ratio |
|---|
| AMTX (Aemetis) | +8.33 % | 1.30 | 93.8 | – |
| ICCC (Immucell) | –1.82 % | 10.25 | 93.1 | 137.53 |
| INO (Inovio) | +7.14 % | 0.90 | 92.8 | – |
| AUBN (Auburn Natl Bancorporation) | +1.51 % | 26.86 | 93.6 | 11.19 |
| NRXS (Neuraxis) | –2.63 % | 7.40 | 92.9 | – |
Company Overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical‑stage pharmaceutical company that develops and commercializes candidate therapies, including the novel drug lenabasum, for inflammatory and fibrotic diseases. The company operates in Europe, Israel, and Australia and is listed on the Nasdaq stock exchange.
